ࡱ>  3bjbjWW 4v55)j j 8l|s (H(ppp /s1s1s1s1s1s1s$uDxUsUsppHjs\\\ppp/s\/s\\hppPyRFUkLss0sk8xxppxkq\UsUs\sxj : ScopeThis policy applies to inpatient, outpatient, and procedural care areas. PurposeThe purpose of this policy is to outline the requirements for administration of medications at Florida Hospital. PolicyMedications are administered only upon a physician's or allied health provider's order and must be verified prior to their administration by use of the Medication Administration Record (MAR) and/or original Physician's Orders. Administration of each medication dose must be documented on the MAR. If a scheduled medication is not administered, the clinician must document not given plus the reason. The Five Rights must be observed when administering medication: Right patient Right time Right medication Right dose Right route of administration The nurse must observe the complete administration of medications. Intravenous infusions and ingestion of bowel or radiology preparations requiring extended time for complete administration are exempt from this requirement. When orders for medications requiring intravenous (IV) administration are received, an IV catheter will be placed to allow administration to patients without existing IV access. The clinician is expected to know the action of each medication prior to administration and to observe the patient for signs of therapeutic results or toxicity. Clinician is expected to use best clinical judgment on whether to call the physician, based on harm or potential for harm. All medications administered within the health care facility shall be administered according to standard medication administration time schedules. The standard medication administration time schedules are outlined in SOP #200.040A: Medication Administration Time Schedules. Exemptions to Standard Medication Administration Time Schedules: Initial doses, Loading doses, STAT, On-Call, Timed or Sequenced doses. For initial doses, the following turn-around times have been defined: STAT: 30 minutes STAT (for drugs that must be mixed, i.e., large volume IV and IV piggyback/syringe): 45 minutes NOW/ASAP: 1 hour Routines: 2 hours Respiratory Therapists are excluded from this policy since medication administration times are driven by P&T approved care plans. Antimicrobials and anticonvulsants should be administered at evenly spaced intervals. Medication administration is identified as Time Critical, Non-time Critical, and Time Specific. (See definitions below and attachment Time Critical Medications.) A Time Critical medication administration is considered "on time" if administered within 30 minutes before or 30 minutes after scheduled administration time. Scheduled doses administered outside of the 30 minute time frame should be documented with the reason for delay or omission, and the provider must be notified. Doses outside the 30 minute time frame should be documented at the time given. Medications omitted without an acceptable clinical reason are considered a medication event and a variance report should be documented in Cerner. Non-time Critical scheduled medications must be given within 1 hour before or after the scheduled time. The first dose of a Time Specific medication may be given as soon as scheduled and then all subsequent doses per the time specific schedule. Medication administration times may be altered based on current clinical practice and/or the professional judgment of the Physician, RPh or RN. When special lab tests are to be done, medications due at that particular time may be omitted or postponed with appropriate documentation on the MAR. Physician must be notified if a scheduled medication is postponed or omitted. Medications omitted or postponed that do not result in harm must be documented in the medical record. Clinician is expected to use best clinical judgment on whether to call the physician, based on harm or potential for harm. No harm does not require immediate reporting to the attending physician, and may be reported first thing in the morning. Administration of insulin should never be omitted without a physician order. Refer to SOP #200.040A: Insulin Administration. Certain medications designated as High Risk/High Alert require a double check by two licensed health care team members prior to administration. Refer to Policy 200.350: High Risk/High Alert Medications. Dose range orders will be administered based on the following parameters: Pain: For pain medication ordered as a range (i.e. 1 2 tablets; 1-2mg), the lowest dose in range should be given as the initial dose. The patients pain is reassessed according to clinically like standards and patient clinical condition. If pain control is inadequate, a second dose may be given to bring the total dose given up to the highest dose in the range. When implementing range orders for pain management, nurses will consider the patients previous exposure to opioids; evaluate the presence of concurrent CNS altering medications, and other co morbid conditions that may reduce the patients toleration to opioid administration. Nausea: For mild nausea (nausea without retching or vomiting) the lowest dose in the range should be given, and then nausea reassessed according to clinically like standards and patient clinical condition. If nausea control is inadequate, a second dose may be given to bring the total dose given up to the highest dose in range. For moderate or severe nausea (nausea with retching or vomiting) the highest dose in the range should be given. Agitation: The lowest dose in the range should be given, and then agitation reassessed according to clinically like standards and patient clinical condition. If agitation control is inadequate, a second dose may be given to bring the total dose given up to the highest dose in range. Sleep: The lowest dose in the range should be given, and if sleep is not attained according to clinically like standards and patient clinical condition, a second dose may be given to bring the total dose given up to the highest dose in range Range frequency PRN orders shall be assessed according to the earliest time (i.e., every 4-6 hours will be assessed every 4 hours) and then reassessed according to clinically like standards and patient clinical condition. The following considerations should be observed prior to administration of any medication: Medications should be identifiable up to the point of administration. Medication in an unmarked container should not be administered. A liquid should not be used if there is a change of color or if there is sediment in a preparation which does not have a "shake well" label on the bottle. Unused liquid medication is never returned to the bottle. Tablets and capsules removed from unit dose packaging will not be returned to supply. When a tablet needs to be cut, a patient specific tablet cutter will be used. When a tablet needs to be crushed, a patient specific pill pouch with Silent Knight Pill crusher will be used. (1 Tablet per pouch). All tablets or capsules will be administered to patients using paper or plastic cups. When administering eye drops the administering clinician will wash hands and put on gloves prior to administration. Medication Errors Any error in medication administration is to be reported to the nurse leader or designee immediately. Medication errors that do not result in harm must be documented in the medical record and a RiskMaster report completed. These do not require immediate reporting to the attending physician, and may be reported first thing in the morning. For allergic reactions, other adverse drug reactions, medication errors or drug incompatibilities which result in harm or need for continued monitoring, clinician must notify provider for treatment orders and complete a RiskMaster report. Refer to Policy #305.750: Clinical (Patient) Event Reporting Process. DefinitionsTime Critical Medications: A limited number of medications that must be administered at the exact time indicated as delayed or early administration of more than 30 minutes may cause harm or sub-therapeutic effect or medications that are scheduled more frequently than every 4 hours. Non-time Critical Medications: Medications that must be given within 1 hour before or after the scheduled time. This includes medication given every 4 hours and less frequently, including daily, weekly and monthly. Time Specific Medications: Agents that should be administered on fixed time schedules to ensure appropriate absorption, distribution, metabolism, reduction of adverse events, and/or prevent drug-drug or drug-food interactions. ReferencesSmith, S.F., Duell, D.J., & Martin B.C. (2012). Clinical Nursing skills: Basic to advanced skills. (8th ed.). New Jersey: Pearson Education Inc. Reference p. 590-606. ISMP. (2011). Guidelines for timely medication administration response to the CMS 30 minute rule. Retrieved www.ismp.org/newsletters/acutecare/articles/20110113.asp. American Association for Respiratory Care. (2008). Inhaled medication administration schedules. Retrieved from  HYPERLINK "http://www.aarc.org/resources/position_statemtns/inhaled_medicaion_administration.html" www.aarc.org/resources/position_statemtns/inhaled_medicaion_administration.html. State Operations Manual Appendix A - Survey Protocol, Regulations and Interpretive Guidelines for Hospitals (2011). 482.25 Condition of Participation: Pharmaceutical Services. Related DocumentsSOP # 200.040A: Insulin Administration SOP # 200.040B: Medication Administration Time Schedules. Available at  HYPERLINK "https://drupal02.floridahospital.org/pharmacy/content/200040-rules-medication-administration" https://drupal02.floridahospital.org/pharmacy/content/200040-rules-medication-administration. Policy # 200.350: High Risk/High Alert Medications Policy # 305.750: Clinical (patient) Event Reporting Approved ByOn File  [Signature - Policy Executive Owner] On File [Print Name - Policy Executive Owner]On File  [Signature - Policy Committee Chair] On File [Print - Policy Committee Chair] Approval DateOn File  [MM/DD/YYYY]On File  [MM/DD/YYYY] Revision HistoryOriginal Date: 02/01/78 (390.102) Replaces: 02/15/91 (390.102) Replaces: 02/15/92 (390.102) Replaces: 03/09/00 (200.040) Replaces: 03/15/01 (200.040) Replaces: 11/14/01 (200.040) Replaces: 12/27/01 (200.040) Replaces: 05/02/02 (200.040)Replaces: 08/30/05 (200.040) Replaces: 10/18/05 (200.040) Replaces: 04/12/06 (200.040) Replaces: 04/20/09 (200.040) Replaces: 09/22/11 (200.040) Replaces: 11/14/11 (200.040) Replaces: 06/26/12 (200.040) Converted to new policy format with 2 SOPs 11/18/2013 Edit links 01/10/2014 (200.040). KeywordsAdministration, administration time, STAT, Dose-range orders, Time-critical     PolicyPolicy # 200.040Rules for Medication Administration Executive Owner: Vice President, Ancillary, Ambulatory, Rehabilitation and Continuum of Care ServicesEffective Date: 11/18/2013Review Date: 01/10/2014 The printed copy is for temporary use only. Always refer to the FH intranet for the current official document.Page  PAGE \* MERGEFORMAT 2 of  NUMPAGES 4 OQRZ f g h l z   ˁyˁncXnhEhOJQJh|hOJQJhEh*OJQJhG{+OJQJh/3h*OJQJhEh"OJQJh"OJQJh/3h"OJQJhEhOJQJh|hOJQJhEhOJQJhEh\OJQJ hEhuhEhuOJQJhEh7JvOJQJhEhu5OJQJ PQRZuggd$Ifgd/3|kd$$Ifl  0~ * ! t0 44 layt/3d$Ifgdlh u__IIII & Fd$If^gd/3 & F Vd<$If^Vgd/3d$Ifgdl|kd$$Ifl  0~ * ! t0 44 layt/3 L& & F&d$If^&gdZ & Fd$If^gdZVd<$If^Vgd/3 & F Vd<$If^Vgd/3 & Fd<$If^gd/3 JKL)68IOR]˿˿ן}n```RFhEh1wOJQJ\hEh1w>*OJQJ\hEhN(N>*OJQJ\hU^hZB*OJQJphhEhN(NB*OJQJphhZhN(NOJQJhN(NOJQJhZOJQJhG{+hN(N5OJQJh/3hG{+6OJQJh/3hN(N6OJQJh/3h/36OJQJhEhN(NOJQJh/3h*OJQJhEh*OJQJh/3OJQJ(F{ee & FVd<$If^VgdU^ & Fd<$If^gdU^ & Fd$If^gd'R & FVd<$If^Vgd'R & Fd<$If^gd'R & Fd$If^gd'R & FVd<$If^Vgd'R '<IXYDEFtttlaVJaVh'Rh"5OJQJh'Rh*OJQJh'Rh"OJQJhOJQJhEh*OJQJh'ROJQJh"OJQJhEh"OJQJh'Rh1wOJQJhEh1wB*OJQJphhEh1w>*OJQJhEh1wOJQJhEhN(N5>*OJQJ\hEhN(N>*OJQJ\hEhN(NOJQJhEhN(NOJQJ\E "#۸硏|qe]NhU^h*CJOJQJaJhU^OJQJhU^h*>*OJQJh8woh*OJQJhtrOJQJhEh*OJQJ#hU^h8wo67B*OJQJphhU^h 6OJQJh8woh OJQJh8wohtrOJQJhU^h6OJQJhU^h*6OJQJhU^h8wo6OJQJhU^hU^6OJQJhU^hQ-(6OJQJ#YZ[wiG m & F d<$If^gd/> & F d$If^gdU^d$IfgdU^ & F&d$If^&gdU^ & F&d<$If^&gdU^ & F&d$If^&gdU^ & F d<$If^gdU^ GPXYZ[dfgw}~hixF G )!*!!⿳֨vk`kh8woh8woOJQJh8wohvOJQJh/>h*OJQJh/>OJQJhtrh*OJQJh/>h*>*OJQJhtrOJQJhEh*OJQJhU^CJOJQJaJh*CJOJQJaJhU^hU^OJQJhU^h*>*OJQJhU^h*CJOJQJaJhU^hU^CJOJQJaJ!G *!!V")###$Y%I&&udx$If^gd/> & F#d<$If^gd/> & F#d$If^gd/> & F"Vd<$If^Vgd/> & F d<$Ifgd/> & F d$Ifgd/> & Fd<$Ifgd/> !""""""'#(###$E$Q$k$X%Y%H&I&Y&Z&a&b&&&&&&&&ļıϱϡxlZ"h/>hN(N5CJOJQJ\aJhEhu5OJQJ hEhu"h/>h~cv6>*CJOJQJaJh/>h/>6CJOJQJaJh/>h6CJOJQJaJhEhOJQJh8woOJQJhEh.EOJQJh/>OJQJh/>hvOJQJhEh/>OJQJhvOJQJhEhvOJQJ&&&'(u)v)w)ugVVEE$d$Ifa$gdA$d$Ifa$gd/>d$Ifgd/>d$Ifgdl|kd $$Ifl  0~ * ! t0 44 layt/3&&&&&&&''''''''''u(v(((((((((u)v)w)x))вР{shaUhEhu5OJQJ hEhuhEh/>OJQJh8woOJQJ%h/>hN(NB*CJOJQJaJph"h/>hA5CJOJQJ\aJ"h/>hN(N5CJOJQJ\aJh/>hG{+CJOJQJaJh/>hACJOJQJaJh/>hN(NCJOJQJaJh/>hA5CJOJQJaJh/>hN(N5CJOJQJaJw)x))+**+,,u___IIVd$If^V`gd/>VdP$If^V`gd/>d$Ifgdl|kd$$Ifl  0~ * ! t0 44 layt/3)**@+A+++++++,,,,,,,,,,,,,--+-,-Ͼ񯤝}u}j_ju_T_LHhAphApOJQJhfh-OJQJhfh/>OJQJhfhG{+OJQJhfOJQJhfhfOJQJhEhu5OJQJhG{+5OJQJ hEhuhEh/>OJQJh/>h~cvCJOJQJaJ h/>hX0JCJOJQJaJ%jh/>hXCJOJQJUaJh/>hXCJOJQJaJh/>h-CJOJQJaJ,,,,-,.b.c.ugYKKKd$Ifgd8wod$Ifgdld$Ifgdfd$IfgdG{+|kd$$Ifl  0~ * ! t0 44 layt/3,---------..+.,.4.5.b.c.d.p.w.x.y....ȽvmaRGmahEhUOJQJjhMhMOJQJUhHhU6OJQJhH6OJQJhEhU5OJQJ hEhuhG{+h/>OJQJhfh~cvOJQJhfhG{+OJQJhfOJQJhfh/>OJQJhfh-OJQJhApB* phI}hAphAp0JOJQJhAphApB* OJQJphI}&jhAphApB* OJQJUphI}c.d.p.x.z........./uuuuuuuuuuuud$Ifgdl|kd$$Ifl  0~ * ! t0 44 layt/3 .........///)/*/+/9/@/A/B/C/O/P/W/X/Y/Z/f/h/i/z/Ŷŧ圕zk`ThEhH5OJQJhEh/>OJQJjhMhMOJQJUjhMhMOJQJUhEhU5OJQJ hEhUhEh[OJQJjhMhMOJQJUjVhMhMOJQJUhHhU6OJQJhH6OJQJhEh OJQJhEhUOJQJjhMhMOJQJU/)/*/+/9/A/C/P/X/Z/g/h/bkd$$Ifl  F~ *  t0     44 layt/3d$Ifgdl h/i/z/////0pbTBBBBd$If^gdHd$Ifgd-d$IfgdlkdK$$Ifl  F~ *  t0     44 layt/3z//0 01'121g1i111111111111111111111yuyuyuyuqmV,jhXh/>OJQJU^JmHnHuhfhAphjhUhEhEOJQJhEhOxOJQJ hEhUhEhUOJQJh~cvOJQJhEhU5OJQJ hEhHhApOJQJ#hG{+hH56B* OJQJphphH56B* OJQJphphHOJQJhEhHOJQJ0-0J0g0000001i11d$Ifgd-d$Ifgdld$If^gdH 1111pbbd$Ifgdlkd$$Ifl  F~ *  t0     44 layt 1111111111111~|r|r|r|r|p dgdugdu|kdU$$Ifl  0~ * ! t0 44 layt/3 11111 222[MMd$Ifgd/3|kd2}$$Ifl0~ * ! t044 laytl$  d$Ifa$gdl$d$Ifa$gdl11112 2 2022232C2D22222222222222222D3J3K3b3c3гЗЗЗ܃{l]]jhlh/>OJQJUh/>6CJOJQJ]aJhfhAph/>hApOJQJh/>OJQJhlh/>OJQJ!h+h/>B*OJPJQJph'h+h/>5B*OJPJQJ\phh/>5OJQJhlh/>5OJQJ hlh/>hlh/>5CJ4OJQJaJ4hlh/>OJQJ^J 223222sed$IfgdG{+d$Ifgd/3~kd}$$Ifl0~ * ! t044 layt/32222sed$IfgdApd$Ifgdl}kdZ~$$Ifl40.*n t044 layt/3222222E3y3}{}ma $$Ifa$gdU^d$IfgdU^}kd~$$Ifl40.* n t044 layt/3c3d3e3i3j3u3v3w3x3y3z3{3|3}3~33333ͼ}yuyuqfhEhEOJQJhhfhAph/>h5h/>OJQJ^J hlh/>hU^h/>OJQJ\hOJQJ\mHnHuhlh/>OJQJ\ jhlh/>OJQJU\hlh/>OJQJmHnHu(jhlh/>OJQJUmHnHuhOJQJmHnHuy3z3{3|3}3~33333}{}}}}}kdz$$Ifl0"*:# t0644 laytG{+ 21h:pu/ =!"#$% $$If!vh#v #v!:V l t0 5 5!yt/3$$If!vh#v #v!:V l t0 5 5!yt/3$$If!vh#v #v!:V l t0 5 5!yt/3$$If!vh#v #v!:V l t0 5 5!yt/3$$If!vh#v #v!:V l t0 5 5!yt/3$$If!vh#v #v!:V l t0 5 5!yt/3DdP  3 3"((DdP  3 3"((DdP  3 3"((DdP  3 3"(($$If!vh#v #v:V l t0 5 5yt/3DdP  3 3"((DdP  3 3"(($$If!vh#v #v:V l t0 5 5yt/3$$If!vh#v #v:V l t0 5 5yt $$If!vh#v #v!:V l t0 5 5!yt/3XtDdknb  s >A?Picture 1RslP>J7 ~s FvslP>J7 JFIF``DuckydC      C  " }!1AQa"q2#BR$3br %&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz w!1AQaq"2B #3Rbr $4%&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz ?((?ÿ!uZӴ f[(?y@,ǀ 7k?h쥥ĶL}onH# !A_nМƟZGkKox7w{{LsIF@ t`҂eLi> y_+⬐o0RA-e[36Sq_Yq~6,7(d,:;pqkg^C moMGizލl?\݊ ཌྷ8(d|wUL]J9o:RSozr]H݄RUe W ?_n_E_~t+ st["yHǙ |)ynYQbqaX$^?F5-d\2^"7m'QVWtVy-kO#o*YvJ>PF9Nx_xN˨D6'*@vGYn)[W|C:=~ A[@c`'UlquԆQEQEQEQEW?U/(__'u~  I͌7sow^,eH#8EeU"gD_1 L f81a_3p8Z΅y5%Z+"gD_1 _"ҮZេbX^HK 3+p.q_r2/)vPN:gB((((((((((((((((ol[c]^=z TjRg.CsNApFE}m#k52My諫9b"cw0ϔA{?o+/5%ȹϛx@1 "cm;e,: Ǿ[K-S]yDc6SH +>3' Kx-}7xJtY3 bF̶3`3"zg~k4uN-7J2:-V?3h"nl_C.]kƏ"?$0,AX=76:_lύ_Mw6n<'qZH2bRwmxKBĖ=g,M_X5.Ncp)I%"f^~_ l_ -Bu(U{xLr&p(9u /4VB٨ iNAEL 4AdFqWGI 7񧄵MBFMv_ZSH~[8 m4?vǯ#6r{%O/V-GC~o}ͻ]4i ρq$6׺|Qy|x*W,XK>3m),O\=Aywŧtk>%U)ate$2AVk{9$~*/{)EVKZmXk9"7!, Oex7|u \7[c4Ku EʶeeT=b(0((o8N ,i,M 2agh> 񦔺߆ydӮf/+Ig9Z1i4R[ና 'f{c"eЄ3 5$=P6hrs_ڟ ?G|M Ok3&ӵg yob碿:4Bޞ}\Rz%-O>ξ9q爴O>F#$mBTkc{||a>ŭNܥ|Z , ] @=xj ධse4~yb5c+I)޵mlcjoom-Ӆt&2{Ґ;ֽ 9sD--uk5.xԳ\eGk{;~QEyoUxW2x jb*nuKϕk7HeUgbQ:Tɻ%ݟOV)Ԩ얭׊Yx÷ƹ6fK{kdYrG Wȿ?-[/W̟3~`~MLZOtnQԗc If۠Y$wFar3~RttSO:׵B5)qV?J?R_W)+7uxskwj͉X@RHV]̻9R?F+xċT[4~Gkt;[MΪ8_-5hdET2&M vަ6Yf`]M];kt,zXc0VvyӳVj}c?i*?t~?8S]J8 =r{W i!x{Ēh[XB١[KY0T_t ߌ P7=xާY/9Lu(f s a9Wo:#4wͳU(J-^+kmXePԌ; 8lC想Ѹng,a"՞4u*?? 0⭃34D{>ɮWZ^[t JBm7x2T+ EOD> j,n{Go1Hw&6߱o3y`hދ%u HQ}}a 6iC/NmTZMҷjx"2梜6V~M}WE[OV*ޑu_3umujI=_H&nּvnʬ96geΚˢFa{Kay>&?أ0x{xZ)+_DҺO{>ͳ]J.ի?| O>2𷋭&|"gٶc]m~_HO?NteG4vc%s$ M"E\3W }x?ύ7_^j%EI( Y&P myI7,S[^]V;X)S{uOnՊ9z^3|=h774DncLPJr@=|-=[f D;ʷX-NAz ]<=iiۯG8O+M#wL~̺Ƨmgm/ϼ ӯMW,Q2@Ig/XU>(AI8D2Fȯo$Pߵ5^ݛZF G?ޚ# ? xbsre{;5D|=UEFVRVzoMyHEׅQ@Q@Q@#BBN^'|VhCew[E/sg$)'hOnxOW]kxծr;\:ȭ!Hĕ-?d ~.?hg+b(+XmWiaA;Vws+O|'/ğ#VMD65lrϕo%sMHe<OXxCӐMB'6veB$|ԶbuxGX|Ent?TL YH̓ٹF;"]*پOS ;'izƣ AOn B9| eO2g؏ xx2MD[2\XE|WGy_[;/a6Q?o+#? -nxbBЏ'j h-#Rڿ :Ҵ}:I|+EmggAon\*"= b]WB34|DcRYk'''ؗs _Zbk*/Dž,GI}KG}ِ06N3mtKL_X{_l:x4t&=֑<r]>G7 wݷbs.." K`߷SX'e/Do&?qFڬ(0HݐBʔsPt?=/l^@i6%I ½%uK־ͣ]1[jUVH̀Q_ (Š(G%Zg5_S3Mt)Qyĝ1KQvwg/(LѦ4?򔏅M[M7Wj_?->;JPWy5s:-$?h2ڪRJq_oO/|c]J^(O];0Z+ksفl XbIP$3_x?J|Czuy_1DKG*h'9'`ݬպ4SpL&&5?,]5OQj2 $.FY//c3Tkմ7\q0$MiArg=[`%7he=EW2v}^5mO62YB>[9N>Z?/<(S||#~?G_ Oer g2A $nDl|G"+ϧRP?3p%tgnSKkO%n{Ӣ]DmcGܱN]jҕSr~=C v?v6&#/6{LSO?k_ÿ?_m*Aio+a;F-#YpncV# { ?Sv=ľv/y$ ؙͲ y1 2-| P?ߵΉ2mAYlrW6VGoi, WHх!7c8v84B^Wr']W_F}=x\ %7Vqoe[[ӷ?f[[y_Ev fD-=7qJ$H{\!x.]:pWouIgq0(;8=YaVl~dY;˰Nm^uAs_?r^c7RC_r~_az?K{_oK_Tz&'=RYg }x{_ƿ9n>SKҤCiPCsksE42xFee<A )k ^6FxyfMOC\\#RI8̐NOrkL9@?o {|;;Gn}b?qU!J~լ5<8xU+|_~2hګy=VcqicnWV2cA_?Z$g N$SAʻ=J{oH`n)#{Oٓ O gS"MF m=IW~dE*V` r- $mO[0sYYmbͷf>,nz8+#q2F[AmbOWFO<60NI$֋uM?*+-cI>4Ф2*-KBoX\+;Xu <)P:R] (((SZׇ5_a圛k[W[Y}0"_57gpZ1K9ƵBZ"c <3^3ñMY\؞CxqXUˏR/[˗K-7@U OsR(?{-umc;Y/* GijRf&vol %ʂqG#0𿀾;v[i>44=zƧW'i#ǁFK+[XdxmpJ=߱qAwZ =>"M%p-9#j`;~O|#?x:]z*#Kr4ςvFEf88%]xYz|8,mgQfB7,% c|*GUoO_WKQ𾟨_k7%w -I} ;w{HD0?exVYntM|5)2K{rf.wAo$t> Xײ~ҟ>|"kQ.4۶%剢2޶Cx]v~؞! =cMOS˴KL_X{%ktuZ?/,gOfw::a޼bW'._c}7׭-,zͲϴq.Xs"sl?g7ػ4u\[wnJ,RGGPF T&YyW@)cf81IlGRsƀ?; EiMs(мI/)$;E֝4+m0c5 r^ ; }sZ𔤞e>б`9? GG~GCпss.qZZk>pPT>~~,̳ԭ㺁e?"9d|C xԀZL/,8'›%|/alNK4P,DrPԽ[ERQE/(LѦ4??TM[M7 |LSfK|Wksol[rK4u\3/~n~!i य़ 5VtҌpvWĿ*sOZKyR?Ν+L_?s{ר?c1Mmxc+K}bx|#Y$nðvP-+?Xm3 KY^=KkkSmmo=v:}tsX  2^o$_7dT~^m;6{LSO?Nأx–Z7%Cځ̯f \K†A[6_7_WĿOOjjs>qcoL}N~|q)/6i Yꮎ9WEa⳺W֩kM).U_wS;I^/ʿF)§`O>_O@B-/@**2 ;>|JF?`.-sxSİŶbKmcQG?_U<DŽs@\y-б/0W>y Ua.j3i[v$Ϝ,=ւk^5~V$?'/\&cm=ࡿ/uV qGd]-T~^21 WX|76ۿy$0Z]yQIeOZ\|Iit_g䓊1IQkusTjGL|=<~"ƽ+&#m.HDy7GFz澼 K>QFWWբA15qGfX֥l='(˖-"Wg 6[NzI^Ϭ^'> α}ii:MR5.;${}ҷ_oohw?l&k,xLgP]\\^ ek6Y BҲ…CB3_x-_?~5hK;FӼ'Z[?#Ωnʈo!utxnX)W`v[Kqusa"Oo+nDŽWc;~ ~l\ٯ:ӮݝGS܉K!_5kk ArWc,ͧ\mSS0:^',-6PӵU C$J2CA^o :^M~i}̖#t/j(>(({q2Dž/ nc\x;xٯW'؟}v5zǿJl |~$pxJ)Tz@_ʿA?bY< |.nwqq<PGwfP2I'xoo-'D__hudzbAGO^m'--+d?\xnOֶ)գ-VpLJ{אR?W?b_SO?jt8&0 K U9$7ϻ'7?'s:G5hΣK`lgsvX ׌~?[_|JKu XX ڵS tQ zgc[g˽Äjzßj)g?S>G7Ik hfIfԋ9P$f?KKqɒ.1Q!،WƯ 9cuxL)ƍmwvgI!|iKeUw:DxI⏈_Sz~VZ2 wN) |J)S.IBOSˬu|P~_kt\xZg`̴lM#8+N??A<ؙu4( vȄ 7)+a?Wo٨avϳ~u-s/v4SpmbX"$j Hp>1'WEk}l',<m`t8<Gp*xr6箭m#Ǘ(7ĺM}ss4WA08sD?rmmVV5,B!v O5֡e}Fdž,x.-Mo"1Wѐ2 #5aq9EɆFH;vco&OsD?r~~Σ=Fk^9hՋ*en9H`|6 ;>U1I pfcU&ʣb*sI&Vh۬Tt|;D5[=OMsiw )#O!KPx 3y;gqa -+z+ bpzk7jRIxO |; t_k9_#&? ~~|4G#xOO=6 kP@y\ ҸXֻJ+\^k.\EYIvm،6[þj%+~2: ~о4΅K=V;V@*;\p 2pExGٞg,Nv ~&yhԔWkfuXz83}C9]_']#U\})G-? 8­T{2HVV@ 澉[HC#$(L4@f%I=IE^#^ܭݷG Fo%bC|Tfr V#oތL )*AEa8(4m(>kG١Ttr_ > A2Eq,[3yjNXw362ĞꯘbGIIvm J\ԩ/I~AEW!QEQE~B /ƹ_MtB=K+g=hSgWԄ~OOѿl$Fe#L +y<&i.wX͍r_)?+ ீ_u-KfѬy֝;A"-ό>Z?k^SOس̈AU&u˾ %-u^+B+n)׌Ȳ̤qNRF}iM}He~4fO&# 8®5C<'di3^%']?Z/8;RR·?E_ d_ͯl4{ kB'` $xS>P] ^Z*>&~ײxB7^1iW#x /o$%f b,.1ߵ7;?Y|[4WGmnM'bA۸ ף!h ~οeާ-^-Kִ x/'V"E\#B>]Hm*f hi_jFF[rjI .Ҳ;~ /!{[ }l;W[>X <:.E)ʀG[g`6Csmst и9UՇ Ak_-^~G>O.xfG;}Z E yL HMf^9IZ7;_4CCty+YV@˕p$B3**8:+6?Ou|Wc[R?l1SOlureuk?:O)  5L ҙ*޿v K6?qԫMfOx5ykolw-=9`MQ$*7CIU=@!=+1?"`Q_/gFO< q#păW<*($#UJXE6ۊIY#)e4'efYQ_ |[Lռ꒼}j/I.3Po"ݙFj7h[a_ r/}vhc\_50S̱\Sf〡*u}j:/%u x>%[b"qc5?5V:/">$Xm4`Gs񝊲|BVʓգ]-u0tUQҕoU}sn_4uQ]b.m%u Â9͟+o['SYC ,zg.3([DҨ+IM(V}]ssL> +:[VӐsE~ k)W!m5|7f[=K>'I{d8* I`߇.֫H5D9X[yd>v=|%Lt[K2>}q6*Psp?wE|=7ωm"xźeCB}OPU- rG";# c>;G^֮,&wY-srq<'STOٮq-<>.TۍOKCtWᾋ +?AY_q 7#HШ>T*'u=&B񾒳 8Nc$0ITxq4%K_..+ Y#{}58.z @# p@U}VʪFZko55sY9Ni٧S^ѡwapq{ #ZKk: Ibe6ᑃ _Rwi߈^oK? ;, .C_x'$* yJe}SmМ:[ԩ%'m- ^K|7~˾\JNDfoZ5Nt rVmm(j_']s?1e+Gқ:{ZWc\ǯL{Jίw I,o׆/ox[!ѾZ fQW~Ē7>|wGۺSbGh6FvVNH,KWy8?b]_גg;V"}B?jh2?QoKlpĉ!!K}vЖ{_-{&4"EյTCe 9%b#8p _|d}ցNkm/ay 3ˆS ^P>K[De(е95w4%6Ʌ$ƣBSx캭O;\!>r 6񅔫WO>+NJ2Aor`ӆ22v͇;p֪ڃ-{^h k%g`98lI>[J| . <ߌ>[wt;;oiW$?c1Hď_-:.+?n39] \ ۝`צ~?Mw6}jfHZKO-ͺZ<TTmzо"px?ƉX}]n\F1yi8 f ? kOOKšLbV l :^@cb-\GKf37>jwQ}+>95۠qc$mm W់4bPäI{.}m.c$˦HQ_'#~37~#h(5-}}n&Oʉ xb/s|iiw il,0k:8Cƒ8re7y 9,6[=1ڨ(0=/u_߰'iCOied*ivV`Khe3Dc|mqjal?E~e&g2McÚڥ֌:2G``ȯ8VTc%Ms%Vگ,j<lNgK*(l^T_KÆe'ڏ$j?Tj_=z{凹.& |>©~QB~>~7It9/su7GF6㍙8wF5y~:~zmuY{#C_8$ RW'a`ܱc(]hO36CHo-?WYۢ5]&I<m'F;˄cHD  ώn>~¿lS"+𵷌lσUK p|tq3+zqEgk7;+|͍yVoi{V_J'N _~'z8q \YUU+n2.'t?Raiaƅh~IN+ºw/i}-ginaI$:Q»J,OFo#᥿O7O7\֡jDRwXAC *`1ЭҒ,.7 :RZɭnᏉ&AVF-=Xc!Uത?bS2. vM!'9 m~0cVy"xGgq{F:W\w_W"5˿ |ou.*QB%2 ETer#UNec/8L:u*UE(OWW9PNteWyݏ?d_~ g xR\XE6pѢYȣ<_p# }&1;>0ǡ߉)w2.T$ېg5_ ~?o_Ʉ:]i.wOn:0YWg<'_oUoޝ}U쏰ʸ U*8hzz;[YvZEvjS"QbIv73 )aU+z<# 'ִ-SNִ}J!=\]Fzitj'ƺeVJ(o8$@aͩ Oc_GڝjKzɹk[fb%bz4;Wg#qU~$Ҽs9kTq^rH!֦݊sW???j /5%gpZFԴsoBA,myUŻ4.3@wzGqU/^u/>TBڋpd"Hg֓A#<~n#3Xh2ǺZv>]0\sO;NO o_ROx#惦{RSmyWkC#aF1n#&l '+p]&Б%uY?>.eϴs Xɯ>,~_য়Gl-5 FFC Lz}nev 0/. o8S||)\>xG\4چgf77Va6 !k/Is6[#C&WnFcBrA|d}G ٳ~$ 3sh֭%vNH@XvKkKOfo,n6T*;26Ƹ)I#R=OQ='t ?X>< Xux"sTfPq_Y~>xtMbx&I$Hk@'8?j|QԵ iznuVkj .L<Oq)S> ">.|اFmŽ3M!,ܖff':z(Š(0=/u_?&~^_}Wmhq4Z9~;?)ς#v5Xc)_7_d *~G?3+s/9/O S@gOH2G< E}G?n߂-&~7v-|A|lJ }ǽ V?|6%ՋpZHۉ -ngNٕOcʼ <C㷂n;m[E ?J|Ï@]aQX*U巯*Sy}J.Gzw6&6~x/:g?i> o"4}vB,칷ȹ ֝~1఺g|%z IXE fO˒RL( bNJt~Vu _J#Z\%Ž!*}A"52Jn!Ҩ/ٗFϺ}OU){veۣg.}[i4~C7/AHBEaI ѱ ߆Jن. 1"ӓ/9oKoj]ou3.3Ai6ѻCk0@]o@E`zU??Mg7+xĚ}mcv`oB@Mؓ/د ,? ׅgK66|h<g53<\"NQmkoӥW OjUmY[׭ړ?|%xOPH3Z 捕 IDmďڍ+)]Q*̒f@K^o t02jZ.;-Vζ!$]o ~^ X 罞driڇEs1N &1^1|izw[~:~Z?E5 St_NW_ <<>%0kZ𧔧b$K r4]"R.Ʈ|eEWR[G y)]~[YޛviPQEswxW;kR*7y*f-ʣ 7.Y_;=āೋw*}8X'm_B:9.m,B^`Į8q^_ WS,&ɥ7aYianãmoGuW>O5ͱ9 >]SQ枉k~XYn[kWxZ}>w?s kԻ7ho>.q~سh?Oojqސ#eBIٟ$erq_~U?t/|_-.˪| hT ծPV3ؼ^9aqRKDψxc F .2Ov_+|u2 Jf y|qr0E>XHƟ EjmjuW/| Ԯ_Bz,nrD\}oTWU|i1 :iȱR>? ,sF죧Z?P-ܵQ )]Z蕭򟂟}wχ{ӭt׭eeq,xu8OZj#45FM֡[E};_'׬,u_& VH3.@7]wW?Oc>-fwYH{WJg4c Bɷl| )&OQ߂߷߂Ú>K Fow%0[mx[o‹{s?<.GyE:Ūr~UPp:C`}Qaׂ˺F_?孺f=d3$?hO$|9]>Rn+\iO.&N>]۞kO̭!]"~Sà\¶=um4)*V)ۖ 0 }s(S )xr$7ɸ\enT3LV..f+|U0sGgM \7p9 Y>:3|՚v;Ӭη%6Ûg`!yH ?_B"1:]VdؿA#}i?|AzU,-]N b= CIjOid~ߴEi^ Ve7+v?WҠ*δԢY i[p$c"`N_/# <<veu\*y[Gog#pqV~-eQUS^ WW'G)дS1_DxhG6$_# kN}3E "<;E&ǰA/@?-C\7fg9Ke<>"6U19 :oދ䇸-Ǚ5L .JpfR1_4M=S|o7"r}pDU .R0Wֿ3 Z[=5tңFŴaX<@pb8CCo| _^".48*ި /FK8bF>Rl)1~mh|S[]"V?fpW2aiWVPq[ (P0i6;QHaEPAEC s %]O1o YYLS_]HZrvDPvmS_@O?O xïxZ/ W^)1/'~-I,ιI^g뛈#V_WWs9Erڎ"s],pg~S? |;ZtNv.';1t\__?o?'MR/LVWkiP 8U'EywcpSZjL&.Z>vI/cWo?ைφIykx7UҖh4 N(*V;:(/^UJMF%JbDo5?DFo4txmvsyU3"~7l)8 f|lxKP>K]X$ H™LjϰHQesjQ^Ke-[7ֵGڮy>NW@<$@nwczi#<ѾCoڥ"kAlqUa}E} ~*ו9UnVDx8oEN4{ xxĺ'lGս($,FRA02 ~Eyye_[9ZJ/(]G^&&Mc:ƫyI.Q P2q_4W.35~XmT|?dd~#K"7GSbc>"@oUW:W_? '_ b7z}ΡjO#`o*[sԣ7E} E|+SZU;N,6 QIZ1VAEW9QEVW||Hމ +O{qe}n0F`ABZ(#SQ&;z=>\D;ļ +_}]pݡt1xF0?^hqX!b|359v~2~8;ZŗEciP J^Y?':?!Ud-v.7]/eᘼGx|Mi zVKvcju ?Ck,JuIPuMc]?m hzw{^Rw8v%I5E!Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@ٗ$$If!vh#v #v!:V l t0,5 5!/  ytl$$If!vh#v #v!:V l t0,5 5!yt/3$$If!vh#v#vn :V l4 t0+,55n yt/3$$If!vh#v#vn :V l4 t0+55n yt/3$$If!vh#v:##v:V l t065:#5ytG{+j 666666666vvvvvvvvv666666>6666666666666666666666666666666666666666666666666hH6666666666666666666666666666666666666666666666666666666666666666662 0@P`p2( 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p8XV~ OJPJQJ_HmH nH sH tH J`J nHNormal dCJ_HaJmH sH tH DA`D Default Paragraph FontRi@R 0 Table Normal4 l4a (k ( 0No List jj ! Table Grid7:V0R@R u0 Balloon Text dCJOJQJ^JaJNN u0Balloon Text CharCJOJQJ^JaJ>@"> u0HeaderdH$.1. u0 Header Char> @B> u0FooterdH$.Q. u0 Footer Charf^@bf \0 Normal (Web)ddd[$\$B*CJOJPJQJaJphB'qB 7Jv0Comment ReferenceCJaJ<@< 7Jv0 Comment TextCJaJ:O: 7Jv0Comment Text Char@j@@ 7Jv0Comment Subject5\FF 7Jv0Comment Subject Char5\6U@6 X0 Hyperlink >*B*phPK![Content_Types].xmlN0EH-J@%ǎǢ|ș$زULTB l,3;rØJB+$G]7O٭V$ !)O^rC$y@/yH*񄴽)޵߻UDb`}"qۋJחX^)I`nEp)liV[]1M<OP6r=zgbIguSebORD۫qu gZo~ٺlAplxpT0+[}`jzAV2Fi@qv֬5\|ʜ̭NleXdsjcs7f W+Ն7`g ȘJj|h(KD- dXiJ؇(x$( :;˹! I_TS 1?E??ZBΪmU/?~xY'y5g&΋/ɋ>GMGeD3Vq%'#q$8K)fw9:ĵ x}rxwr:\TZaG*y8IjbRc|XŻǿI u3KGnD1NIBs RuK>V.EL+M2#'fi ~V vl{u8zH *:(W☕ ~JTe\O*tHGHY}KNP*ݾ˦TѼ9/#A7qZ$*c?qUnwN%Oi4 =3N)cbJ uV4(Tn 7_?m-ٛ{UBwznʜ"Z xJZp; {/<P;,)''KQk5qpN8KGbe Sd̛\17 pa>SR! 3K4'+rzQ TTIIvt]Kc⫲K#v5+|D~O@%\w_nN[L9KqgVhn R!y+Un;*&/HrT >>\ t=.Tġ S; Z~!P9giCڧ!# B,;X=ۻ,I2UWV9$lk=Aj;{AP79|s*Y;̠[MCۿhf]o{oY=1kyVV5E8Vk+֜\80X4D)!!?*|fv u"xA@T_q64)kڬuV7 t '%;i9s9x,ڎ-45xd8?ǘd/Y|t &LILJ`& -Gt/PK! ѐ'theme/theme/_rels/themeManager.xml.relsM 0wooӺ&݈Э5 6?$Q ,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{P8g/]QAsم(#L[PK-![Content_Types].xmlPK-!֧6 0_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!0C)theme/theme/theme1.xmlPK-! ѐ' theme/theme/_rels/themeManager.xml.relsPK] +v  !&),-.z/1c33 !#%')+-059 G &w),c./h/01112222y33"$&(*,./1234678:@###,%%%+XXf~!T # @H 0(  0(  B S  ?_GoBackd&+i'+))))))))))**J+e+i+x+++)))))))))++%%+% 'i)))))))))D*D*i*}********D+J+e+i+x+|+++#*V,- a^]L^T;0 :^L? >fsT( h&,Ȕ|4&h~y1DE.Zhz9`Q/l(k/?)7o$G<"tO<( S=x,NAz~y%H~ DN]|4-`F`qe"|&g$Spi'h2/HnteZEp Ks,8HttvQHFuDL}}nQR(A>h ^`o(hH.^`OJQJ^Jo(o p^p`OJQJo( @ ^@ `OJQJo(^`OJQJ^Jo(o ^`OJQJo( ^`OJQJo(^`OJQJ^Jo(o P^P`OJQJo(h ^`hH.h ^^^`hH.h . L^. `LhH.h  ^ `hH.h ^`hH.h L^`LhH.h n^n`hH.h >^>`hH.h L^`LhH.^`.^`.pL^p`L.@ ^@ `.^`.L^`L.^`.^`.PL^P`L. ^`o(hH. ^`hH. pL^p`LhH. @ ^@ `hH. ^`hH. L^`LhH. ^`hH. ^`hH. PL^P`LhH.h ^`hH.h ^`hH.h z L^z `LhH.h J ^J `hH.h ^`hH.h L^`LhH.h ^`hH.h ^`hH.h ZL^Z`LhH. ^`OJQJo(-^`OJQJ^Jo(o p^p`OJQJo( @ ^@ `OJQJo(^`OJQJ^Jo(o ^`OJQJo( ^`OJQJo(^`OJQJ^Jo(o P^P`OJQJo(h ^`hH.h ^`hH.h pL^p`LhH.h @ ^@ `hH.h ^`hH.h L^`LhH.h ^`hH.h ^`hH.h PL^P`LhH.h ^`6hH.h ^`hH.h pL^p`LhH.h @ ^@ `hH.h ^`hH.h L^`LhH.h ^`hH.h ^`hH.h PL^P`LhH. h^h`OJQJo(-8^8`OJQJ^Jo(o ^`OJQJo(  ^ `OJQJo( ^ `OJQJ^Jo(o x^x`OJQJo( H^H`OJQJo(^`OJQJ^Jo(o ^`OJQJo( ^`OJQJo(^`OJQJ^Jo(o p^p`OJQJo(- @ ^@ `OJQJo(^`OJQJ^Jo(o ^`OJQJo( ^`OJQJo(^`OJQJ^Jo(o P^P`OJQJo(h^`B*phhH.h ^`hH.h z L^z `LhH.h J ^J `hH.h ^`hH.h L^`LhH.h ^`hH.h ^`hH.h ZL^Z`LhH.  ^`o(hH. ^`hH. pL^p`LhH. @ ^@ `hH. ^`hH. L^`LhH. ^`hH. ^`hH. PL^P`LhH.h ^`hH.h ^`hH.h pL^p`LhH.h @ ^@ `hH.h ^`hH.h L^`LhH.h ^`hH.h ^`hH.h PL^P`LhH.h ^`hH.h ^`hH.h pL^p`LhH.h @ ^@ `hH.h ^`hH.h L^`LhH.h ^`hH.h ^`hH.h PL^P`LhH.^`B*OJQJo(ph^`OJQJ^Jo(o p^p`OJQJo( @ ^@ `OJQJo(^`OJQJ^Jo(o ^`OJQJo( ^`OJQJo(^`OJQJ^Jo(o P^P`OJQJo(h ^`hH.h ^`hH.h pL^p`LhH.h @ ^@ `hH.h ^`hH.h L^`LhH.h ^`hH.h ^`hH.h PL^P`LhH.  h^h`o(hH. ^`hH. pL^p`LhH. @ ^@ `hH. ^`hH. L^`LhH. ^`hH. ^`hH. PL^P`LhH.h^`B*o(phhH.^`OJQJ^Jo(o p^p`OJQJo( @ ^@ `OJQJo(^`OJQJ^Jo(o ^`OJQJo( ^`OJQJo(^`OJQJ^Jo(o P^P`OJQJo(h ^`hH.h ^`hH.h pL^p`LhH.h @ ^@ `hH.h ^`hH.h L^`LhH.h ^`hH.h ^`hH.h PL^P`LhH. ^`OJQJo(^`OJQJ^Jo(o p^p`OJQJo( @ ^@ `OJQJo(^`OJQJ^Jo(o ^`OJQJo( ^`OJQJo(^`OJQJ^Jo(o P^P`OJQJo( ^`o(hH. ^`hH. pL^p`LhH. @ ^@ `hH. ^`hH. L^`LhH. ^`hH. ^`hH. PL^P`LhH.h^`B*o(phhH.^`OJQJ^Jo(o p^p`OJQJo( @ ^@ `OJQJo(^`OJQJ^Jo(o ^`OJQJo( ^`OJQJo(^`OJQJ^Jo(o P^P`OJQJo( &^&`67B*o(phhH. ^`hH. pL^p`LhH. @ ^@ `hH. ^`hH. L^`LhH. ^`hH. ^`hH. PL^P`LhH. ^`OJQJo(^`OJQJ^Jo(o p^p`OJQJo( @ ^@ `OJQJo(^`OJQJ^Jo(o ^`OJQJo( ^`OJQJo(^`OJQJ^Jo(o P^P`OJQJo(h ^`hH.h ^`hH.h pL^p`LhH.h @ ^@ `hH.h ^`hH.h L^`LhH.h ^`hH.h ^`hH.h PL^P`LhH. ^`B*ph.^`.pL^p`L.@ ^@ `.^`.L^`L.^`.^`.PL^P`L. ^`B*ph.^`.pL^p`L.@ ^@ `.^`.L^`L.^`.^`.PL^P`L.h ^`hH.h ^`hH.h pL^p`LhH.h @ ^@ `hH.h ^`hH.h L^`LhH.h ^`hH.h ^`hH.h PL^P`LhH.h h^h`o(hH. 8^8`OJQJo(- ^`OJQJo(  ^ `OJQJo( ^ `OJQJ^Jo(o x^x`OJQJo( H^H`OJQJo(^`OJQJ^Jo(o ^`OJQJo(h &^&`hH.h ^`hH.h  L^ `LhH.h  ^ `hH.h f^f`hH.h 6L^6`LhH.h ^`hH.h ^`hH.h L^`LhH. ^`o(hH. ^`hH. pL^p`LhH. @ ^@ `hH. ^`hH. L^`LhH. ^`hH. ^`hH. PL^P`LhH.h&^&`6B*o(phhH.h ^`hH.h  L^ `LhH.h  ^ `hH.h f^f`hH.h 6L^6`LhH.h ^`hH.h ^`hH.h L^`LhH. ^`OJQJo(^`OJQJ^Jo(oh p^p`o(hH. @ ^@ `OJQJo(^`OJQJ^Jo(o ^`OJQJo( ^`OJQJo(^`OJQJ^Jo(o P^P`OJQJo( ^`OJQJo(^`OJQJ^Jo(o p^p`OJQJo( @ ^@ `OJQJo(^`OJQJ^Jo(o ^`OJQJo( ^`OJQJo(^`OJQJ^Jo(o P^P`OJQJo(h ^`hH.h ^`hH.h pL^p`LhH.h @ ^@ `hH.h ^`hH.h L^`LhH.h ^`hH.h ^`hH.h PL^P`LhH.#O<^|&gDN]1DE.,!qefzs/Hn? L}}#Q-(*G{+F.Ov./3n5'9Z;z;,#AB-iD.E1YGYJYMN(NsP5ZA-[t[\U^hai5k,kn8wo!pAptr7Jv~cv};fuT'R-\+TElM/BfZi+  56G=v!r |Mdy|vXExSH/1w5Z"T[ZOx_ HBiMnH))@ +@UnknownG*Ax Times New Roman5Symbol3. *Cx Arial7.@Calibri5. .[`)Tahoma?= *Cx Courier New;WingdingsA$BCambria Math"1h%G%G5;@#L@#L0))>QHP  $P!2!xx #Rules for Medication AdministrationRobert PurintonPrevost, Rebecca#                           ! " Oh+'0t  $ 0 < HT\dl$Rules for Medication AdministrationRobert PurintonNormalPrevost, Rebecca2Microsoft Office Word@@~@]ay@]ay@#՜.+,D՜.+,X hp   PersonalL) %Rules for Medication Administration TitleTkw    c sWwG _PID_HLINKS Lead Author!p3cfee40c04d4715aeecb674ef3503bc Review YearsMgd Document Version!l69e80edf61741f1906514a934a939c4Bdisplay_urn:schemas-microsoft-com:office:office#Lead_x0020_Author ReviewDate Standard Chapter Managed Document ID Related DocumentsEffective Date!hcaa0a9b19004e24be32767ff3d3a40fExecutive Owner Title TaxCatchAllLeadA ^]https://drupal02.floridahospital.org/pharmacy/content/200040-rules-medication-administrationN"Whttp://www.aarc.org/resources/position_statemtns/inhaled_medicaion_administration.html11018Pharmacy Services|f2cec7d5-0107-4093-bb2a-2fe85a02ec97Morris, Candice2013-11-06T00:00:00Z<35;#Pharmacy Services|f2cec7d5-0107-4093-bb2a-2fe85a02ec97200.040

​#*#200.040A Insulin Administration SOP
#*#200.040B Medication Administration Time Schedules SOP
#*#200.350 High Risk/High Alert Medications Policy
#*#305.750 Clinical (patient) Event Reporting Policy

2013-11-18T00:00:00Z|Vice President Ancillary, Ambulatory, Rehabilitation & Continuum of Care Services|6a75ed6b-a0ee-47f8-befa-2c768e37720126;#Vice President Ancillary, Ambulatory, Rehabilitation & Continuum of Care Services|6a75ed6b-a0ee-47f8-befa-2c768e37720135;#Pharmacy Services|f2cec7d5-0107-4093-bb2a-2fe85a02ec97;#26;#Vice President Ancillary, Ambulatory, Rehabilitation & Continuum of Care Services|6a75ed6b-a0ee-47f8-befa-2c768e377201  !"#$%&'()*+,-./0123456789:;=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|~Root Entry FyData <1Table}yWordDocument4vSummaryInformation(DocumentSummaryInformation8MsoDataStore `ʀyPyRVA1WUYOCO==2`ʀyOyItem  6Properties@IGZCU4C5C0BQ==2 `ʀy0GyItem  PropertiesO1N0R40A0QGW==2`ʀy@yItem PropertiesSSWWGR5E4XDIA==2`ʀy@PyItem #Properties'@WVTOCO3FQ==2`ʀyPyItem ,Properties0UCompObj6r This value indicates the number of saves or revisions. The application is responsible for updating this value after each revision.   !"$%&()*+-./123457 DocumentLibraryFormDocumentLibraryFormDocumentLibraryForm   F Microsoft Word 97-2003 Document MSWordDocWord.Document.89q